BioLine Rx (XTAE:BLRX) Book Value per Share : ₪0.05 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Book Value per Share?

BioLine Rx's book value per share for the quarter that ended in Dec. 2023 was ₪0.05.

During the past 12 months, BioLine Rx's average Book Value Per Share Growth Rate was -77.70% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -42.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -43.90% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -31.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioLine Rx was 8.20% per year. The lowest was -49.90% per year. And the median was -28.65% per year.

BioLine Rx's current price is ₪0.176. Its book value per share for the quarter that ended in Dec. 2023 was ₪0.05. Hence, today's PB Ratio of BioLine Rx is 3.83.

During the past 13 years, the highest P/B Ratio of BioLine Rx was 8.26. The lowest was 3.63. And the median was 6.37.

BioLine Rx Book Value per Share Historical Data

The historical data trend for BioLine Rx's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Book Value per Share Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Book Value per Share

Get a 7-Day Free Trial

0.73

0.24

0.36

0.21

0.05

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Book Value per Share	Get a 7-Day Free Trial															0.21	0.16	0.09	0.05	0.05

Competitive Comparison of BioLine Rx's Book Value per Share

For the Biotechnology subindustry, BioLine Rx's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's PB Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's PB Ratio falls into.

BioLine Rx Book Value per Share Calculation

BioLine Rx's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(49.66	-	0.00)	/	1,086.59
	=	0.05

BioLine Rx's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(49.66	-	0.00)	/	1,086.59
	=	0.05

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

BioLine Rx (XTAE:BLRX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.

BioLine Rx Book Value per Share Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Book Value per Share

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.